Cumberland Pharmaceuticals (CPIX) Q3 2024 earnings summary

Executive summary

• Q3 2024 net revenues were $9.1 million, with year-to-date revenues at $27–27.4 million; Sancuso and Caldolor grew, while Kristalose and Vibativ declined, and net loss for Q3 was $1.5 million or $0.11 per share, with adjusted loss at $0.26 million or $0.02 per share.

• Kristalose and Sancuso were leading contributors, with Sancuso benefiting from new patient programs and expanded oncology sales, and Kristalose expanding Medicaid coverage.

• Caldolor supported by new clinical data showing reduced adverse reactions and improved healthcare utilization, and international expansion with new regulatory submissions.

• Vibativ sales were negatively affected by hurricane-related supply chain disruptions but is positioned for international growth, with launches in Saudi Arabia and ongoing registration in China and South Korea.

• Ifetroban program for Duchenne Muscular Dystrophy received FDA Orphan Drug and Rare Pediatric Disease designations, and CET's delirium treatment met safety endpoints in Phase II.

Financial highlights

• Q3 2024 net revenue: $9.1 million; Kristalose $3.6M, Sancuso $2.6M, Caldolor $1.3M, Vibativ $1M.

• Year-to-date net revenue: $27–27.4 million; Kristalose $10.9M, Sancuso $6.6M, Vibativ $5.1M, Caldolor $3.6M.

• Q3 2024 operating expenses: $10.8 million, down $1 million year-over-year; year-to-date: $32 million.

• Q3 2024 net loss: $1.5 million ($0.11/share); adjusted loss: $0.26 million ($0.02/share).

• Cash and cash equivalents at quarter-end: $17.5 million; total assets: $76.7 million; liabilities: $52.3 million; equity: $24.8 million.

Outlook and guidance

• Expectation of stronger brand shipments in Q4, with full-year performance to be reported next quarter.

• Ongoing acquisition initiative to add select FDA-approved brands and plans to complete and analyze ifetroban clinical studies.

• Continued advocacy for Caldolor's Medicare reimbursement and expansion of Medicaid coverage for Kristalose, with evaluation of options after CMS excluded Caldolor from NOPAIN Act reimbursement.

• Management expects to continue paying minimal income taxes due to $51.9 million in federal net operating loss carryforwards.

• CET planning pivotal FDA study for new delirium treatment and advancing internal bleeding diagnostic product.